TransCode Therapeutics Inc. RNAZ
1.69
0.04
2.42%
as of 25 Sep
- Market cap
- $27.9M
- P/E
- 0.0×
Follow RNAZ
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 3.25 | 2.05 | 8.97 | 1.70 | 1.28 | 2.56 | 6.29 |
Net Debt/EBITDA |
— | (1.58) | (1.73) | 3.41 | 0.27 | 0.15 | 0.38 | 0.64 |
Debt/Assets |
0.00% | 428.15% | 197.72% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (0.85) | (0.61) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.84 | 0.21 | 0.77 | 0.90 | 0.97 | 0.79 | 0.54 |
Capex/Depreciation |
— | — | — | (5.92) | (1.02) | (0.07) | (0.04) | (0.06) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 27.03% | 104.04% | (80.53%) | (148.57%) | (759.85%) | 8,883.62% | (872.24%) | |
| — | (560.41%) | (368.51%) | (57.04%) | (115.08%) | (290.74%) | (269.34%) | (42.75%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (428.81%) | (549.82%) | (33.54%) | (542.01%) | (1,708.53%) | (383.84%) | (192.31%) |
Average Days of Receivables |
— | — | — | — | 0.00 | — | — | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.86 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.79) | (0.11) | (0.65) | 0.00 | (90,550.50) | (1,060.14) | (28.31) |
Cash per Share |
— | 0.32 | 0.18 | 2.47 | 0.00 | 13,838.00 | 461.20 | 25.83 |
Shareholders Equity per Share |
— | (1.70) | (0.74) | 2.42 | 0.00 | 8,204.00 | (160.21) | 14.99 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (1.70) | (0.74) | 2.42 | 0.00 | 8,204.00 | (160.21) | 14.99 |
Free Cash Flow |
— | (0.51) | (0.49) | (5.52) | (15.86) | (18.11) | (13.36) | (19.52) |
Working Capital |
— | 0.14 | 0.43 | 20.20 | 3.03 | 0.96 | 4.32 | 18.49 |
Capital Expenditures |
— | — | — | (0.25) | (0.10) | (0.04) | (0.02) | (0.01) |
Net Current Asset Value |
— | (1.11) | (3.63) | 20.20 | 3.03 | 0.93 | (2.22) | (130.08) |
| Other line items | ||||||||
Quick Ratio |
— | 3.25 | 2.04 | 8.22 | 1.23 | 0.79 | 2.10 | 5.37 |
Depreciation/Fixed assets |
— | — | — | 0.21 | 0.47 | 4.28 | 10.37 | 0.31 |
Cash ROIC |
— | (1,461.21%) | 99.90% | (13.27%) | (194.55%) | (412.74%) | (353.01%) | (70.65%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.79) | (0.11) | (0.63) | 0.00 | (90,372.50) | (1,058.41) | (28.30) |
Capex per Share |
— | 0.00 | 0.00 | (0.03) | 0.00 | (178.00) | (1.73) | (0.01) |
Average Receivables |
— | — | — | — | — | — | — | 0.66 |
Average Payables |
— | 0.20 | 0.20 | 1.44 | 3.43 | 3.70 | 2.88 | 3.10 |
Average Assets |
— | 0.11 | 0.64 | 12.00 | 15.26 | 6.38 | 6.23 | 84.85 |
Average Common Equity |
— | (2.25) | (2.25) | 8.50 | 11.82 | 2.44 | (0.19) | 4.16 |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates